In the latest trading session,, 0.93 million 10x Genomics Inc (NASDAQ:TXG) shares changed hands as the company’s beta touched 1.99. With the company’s most recent per share price at $10.86 changing hands around $0.21 or 2.01% at last look, the market valuation stands at $1.36B. TXG’s current price is a discount, trading about -127.99% off its 52-week high of $24.76. The share price had its 52-week low at $6.78, which suggests the last value was 37.57% up since then.
Analysts gave the 10x Genomics Inc (TXG) stock a consensus recommendation rating of Hold, calculated at a mean rating of 2.26. If we narrow down to specifics, the data shows that 0 out of 8 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 5 recommended TXG as a Hold, 3 felt it is a Buy and 0 rated the stock as Underweight.
10x Genomics Inc (NASDAQ:TXG) trade information
Instantly TXG is in green as seen in intraday trades today. With action 16.32%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -24.35%, with the 5-day performance at 16.32% in the green. However, in the 30-day time frame, 10x Genomics Inc (NASDAQ:TXG) is 14.48% up.
The consensus price target for the stock as assigned by Wall Street analysts is 25, meaning bulls need an upside of 56.56% from its recent market value. According to analyst projections, TXG’s forecast low is 24 with 46 as the target high. To hit the forecast high, the stock’s price needs a -323.57% plunge from its current level, while the stock would need to soar -120.99% for it to hit the projected low.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -36.10%. The 2025 estimates are for 10x Genomics Inc earnings to increase by 20.48%, but the outlook for the next 5-year period is at 25.49% per year.
TXG Dividends
10x Genomics Inc is expected to release its next quarterly earnings report in July.
VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 8.4863% or 10.19 million shares worth $198.18 million as of 2024-06-30.
Among Mutual Funds, the top two as of Apr 30, 2025 were ARK ETF Trust-ARK Innovation ETF and ARK ETF Trust-ARK Genomic Revolution ETF . With 8.71 shares estimated at $95.13 million under it, the former controlled 7.84% of total outstanding shares. On the other hand, ARK ETF Trust-ARK Genomic Revolution ETF held about 2.92% of the shares, roughly 3.24 shares worth around $35.38 million.
